Background: Cutibacterium (C. acnes) lipase activity can be reduced by topical antifungal cream called ketoconazole (KTZ). Additionally, it contains anti-inflammatory and anti-androgenic properties. The aim of this study was to evaluate the efficacy of topical ketoconazole 2% cream versus placebo in the treatment of mild and moderate acne vulgaris. Patients & Methods: 40 patients presented by mild and moderate acne were instructed to apply ketoconazole 2 % cream to the right half of the face and placebo to the left half of the face twice daily for 8 weeks Results: The mean percent reduction of inflammatory lesions (papules and pustules) and Total lesions count from baseline was significantly higher in ketoconazole than placebo. There was a statistically significant decrease in acne severity assessed by IGA score in both sides. The success rate of ketoconazole was significantly higher than placebo. In ketoconazole side, 17.5% of patients considered clear versus12.5%in control side and 52.5% almost clear versus 35% in control side. There was a statistically significant negative relationship between the therapeutic response and number of pustules in each side. Conclusion: Topical ketoconazole 2% can be an effective and safe treatment option for mild and moderate acne vulgaris.
No takes yet. Share an insight, caveat, or question.
Khater et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: